Organic Active Ingredients TRIZ Cases

Tripeptide antagonists block MRGPRX2 receptors to inhibit Substance P-induced itch, addressing the unmet need for non-histamine mediated treatments.

Merging Hsp90 and mTOR inhibitors suppresses phospho-AKT up-regulation, resolving the efficacy trade-off in single-agent cancer treatments.

A sublingual spray formulation containing naloxone and antioxidants delivers the drug directly through mucosal tissue.

Combining nanoscale kaolin and chitosan overcomes single-agent limitations for severe hemorrhage control.

Catalytic reduction of lactoylpterin and oxidation of tetrahydrolactoylpterin produce sepiapterin with high yield.

E1/E2b-deleted Ad5 vectors overcome pre-existing immunity barriers, enabling repeated vaccinations and sustained transgene expression.

A vaginal ring segments estrogen delivery to alleviate genitourinary syndrome of menopause symptoms while minimizing systemic cancer risks.

Silica and clay adsorbents remove sterols from marine triglyceride oils without thermal degradation or chemical contamination.

Specific JNK3 inhibitors address the lack of effective treatments for neurodegenerative disorders by reducing neuronal apoptosis.

Periodic reapplication of 5 wt-% capsaicin patches resets TRPV1 receptor sensitivity, converting initial non-responders to achieve sustained pain relief.

A regenerative composition containing amino acids and insulin stimulates cellular signaling pathways to induce tissue repair.

Phosphorothioate IL-34 antisense oligonucleotides reduce mRNA expression to provide sustained symptom relief without broad side effects.

Reactive oxygen species scavengers alter electrogram characteristics to identify atrial fibrillation hotspots for targeted ablation.

Segmented synthesis removes aldehyde and dimer contaminants to ensure 99.0% purity.

Substituted benzimidazole compounds inhibit TAK1 kinase activity, reducing off-target effects on MAP2K family members to improve therapeutic selectivity.

LNA-modified antisense oligonucleotides inhibit ATXN2 expression to address inadequate reduction of ataxin 2 in neurodegenerative disease treatments.

Cobalt protoporphyrin IX mobilizes leukocytes by elevating G-CSF levels, replacing complex recombinant protein production with simpler chemical synthesis.

Yeast beta-glucan emulsion with squalane delivers anti-viral activity, resolving the trade-off between immune stimulation and formulation stability.

Antisense oligonucleotides inhibit chemoresistant cancer stem cells by targeting specific microRNAs, restoring drug sensitivity for osteosarcoma therapy.

Pyrazolo pyrimidinone compounds inhibit PDE9A to treat neurological diseases lacking effective therapies.

Clonal hematopoiesis biomarkers detect high-risk patients early, enabling timely anti-cytokine therapy to prevent life-threatening organ damage.

Replacing an oily base with a water-soluble polymer matrix eliminates drug affinity issues and improves transdermal absorption of beraprost.

Formula I derivatives compete with ATP at the kinase domain, resolving incomplete pathway disruption from rapamycin analogues.

Steam sterilizing pH-adjusted baclofen solutions minimizes 4-CPP degradation while preventing particulate formation, ensuring stable injectable formulations.

Electrophilic warhead forms covalent bond with cysteine residue to irreversibly inhibit kinase activity while maintaining high selectivity across FGFR isoforms.

Azaindolylphenyl sulfonamides inhibit B-RAF V600E kinase, reducing tumor cell proliferation in melanoma and other cancers.

Formula I compounds selectively target CDK8/19 ATP pockets, resolving the contradiction between cancer efficacy and normal cell safety.

siRNA-loaded nanoparticles silence XBP1 in tumor-associated dendritic cells, resolving ER stress-induced immunosuppression to enhance anti-tumor immunity.

Trometamol buffers an oral nicotine spray to adjust saliva pH, eliminating off-notes while enhancing nicotine bioavailability.

Injectable material forms a gastrointestinal therapeutic restriction, avoiding invasive surgery morbidity and mortality.

Acid-resistant biopolymer microspheres protect Bryostatin-1 from gastric acid degradation, enabling effective oral treatment for neuro-degenerative diseases.

Segmented polymers with hydrolyzable acetal groups enable selective aldehyde introduction, resolving dissociation issues at physiological pH.

PD-L1 axis binding antagonists block inhibitory receptor signaling to restore T cell function, addressing limited survival rates in solid tumor treatments.

Trichloroacetic acid salts of 5-aminolevulinic acid reduce skin irritation and hygroscopicity while improving stability for photodynamic therapy.

A sequential injection method using crosslinked hyaluronic acid to restore facial volume in the midface region.

Negishi coupling synthesizes activin receptor-like kinase inhibitors with higher purity and yield, reducing by-product formation.

Aceclidine activates M1 and M3 receptors for near vision while tropicamide prevents distance vision deterioration and ciliary spasms.

Fluoro-substituted beta-hydroxyethylamines activate beta2-adrenergic receptors to increase glucose uptake while minimizing cAMP release side effects.

Fractionated plant powder extract adsorbs heavy metal ions through carboxylic acid groups, replacing costly synthetic flocculants with a renewable material.

Quinazolinone compounds associate with biologically available ionic iron to lower intracellular concentrations in neuronal cells.

Kluyveromyces lactis ATCC 8585 consumes monosaccharides and disaccharides during fermentation, resolving the trade-off between purity and process complexity.

Allosteric modulation of D1 receptors by isoindoline derivatives improves selectivity and reduces adverse effects compared to orthosteric agonists.

Small molecules stabilize transthyretin tetramers, reducing amyloid formation and cell dysfunction in amyloidosis.

Partial agonist compounds activate STING to induce type I interferon production for targeted immune stimulation.

Baicalein suppresses inflammatory responses in allergic diseases by inhibiting intracellular STAT5 phosphorylation and preventing TSLP-TSLPR binding.

Macrocyclic indole derivatives overcome clinical efficacy limits by blocking MCL-1 anti-apoptotic function.

Metabolic labeling of cancer cell surfaces using azidosugar moieties and trigger-responsive linkers overcomes low protein density.